Scientists have discovered epigenetic changes (i.e. chemical changes to a gene that do not alter the DNA sequence) in individuals with schizophrenia and bipolar disorder. This is the first epigenome-wide investigation in psychiatric research, and this groundbreaking data may be a significant step on the journey to fully understanding major psychosis.
Dr. Arturas Petronis, senior scientist in the Krembil Family Epigenetic Laboratory at the Centre for Addiction and Mental Health (CAMH), and his team studied 12,000 locations on the genome using an epigenomic profiling technology developed at CAMH. Approximately one in every two hundred of these genes showed an epigenetic difference in the brains of psychiatric patients.
Significantly, these changes were noted on genes involved in neurotransmission (the exchange of chemical messages within the brain), brain development, and other processes linked to disease origins.